Quantitative detection of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer

WENHUA XIAO*, HUIXIA ZHAO*, WEIWEI DONG, QUIWEN LI, JIANHUA ZHU, GUANGHUI LI, SHUFANG ZHANG and MING YE

Department of Oncology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, P.R. China

Received November 4, 2013; Accepted October 15, 2014

DOI: 10.3892/ol.2014.2815

Abstract. The present study explored the use of methylated NDRG4 gene as a candidate biomarker for diagnosis of colorectal cancer (CRC). Methylated NDRG4 gene expression from colorectal carcinoma tissue, paracarcinoma tissues, stools, blood and urine were detected successfully in DNA samples from 84 patients, by nested methylation-specific polymerase chain reaction and denaturing high-performance liquid chromatography. The sensitivity and specificity of methylated NDRG4 gene expression for us as a biomarker in colorectal cancer was analyzed and compared with 16 age-matched healthy controls. The positive detection rate of methylated NDRG4 was 81% in carcinoma tissue, 8.3% in paracarcinoma tissues, 54.8% in blood, 72.6% in urine and 76.2% in stools. Considering the convenience of the acquisition of urine samples, an additional group of 76 patients with CRC were recruited for verification of detecting methylated NDRG4 in the urine. The positive detection rate of methylated NDRG4 was 72.4% (55/76) in this cohort. The detection of methylated NDRG4 in stools and urine could be used as a novel diagnostic technique for highly sensitive and specific detection of CRC. Due to the ease of collecting urine samples, this novel method could be a potential biomarker for early diagnosis of CRC.

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality and the third most prevalent cancer in western countries (1-3). CRC is curable in its early stages, whereas in the advanced stages, the survival time is <30 months. Early diagnosis and treatment is therefore of high importance (4). The current routine method of screening is by colonoscopy. The use of colonoscopy, however, is not an ideal method since it is an invasive technique and the use of colonoscopy screening could be limited in high-risk populations, in particular in low-income patients (5,6). The fecal occult blood test for CRC is an additional screening method that is currently performed, however this test is limited due to its low sensitivity (7). Studies have therefore been performed to improve the diagnostic biomarkers available for detection of CRC (8,9).

Abnormal DNA methylation is an early event that occurs during tumorigenesis, and numerous abnormally hypermethylated genes have been identified in cases of CRC (10-12). Gene methylation status could therefore be used as a molecular diagnostic indicator (13). DNA from CRC cells can be readily obtained from feces samples, which contain both normal and CRC-shedded colorectal epithelial cells, from which DNA can be extracted (14). In addition, the alkaline environment of the intestine is conducive to the preservation of DNA (15). NDRG4 is a member of the NDRG gene family and is a known tumor suppressor gene (16,17). A previous study suggested that the NDRG4 gene is present in CRC tumor tissues and bodily fluids with high stability and repeatability (16).

The present study analyzed the methylated NDRG4 gene expression in 87 patients with CRC by nested methylation-specific polymerase chain reaction (n-MSP) combined with denaturing high-performance liquid chromatography (DHPCL). The samples were collected from carcinoma and paracarcinoma tissues, blood, urine and feces of patients with CRC. The sensitivity and specificity of methylated NDRG4 gene detection in these samples were compared with those in healthy controls, and assessed for use as a potential candidate biomarker for the diagnosis of CRC.

Materials and methods

Patient enrollment. The present study was approved by the Institutional Review Boards of the General Hospital of PLA (Beijing, China). The CRC and pericarcinoma tissues were obtained from surgeries undertaken between June 2010 and August 2011. All the samples were confirmed by pathology. All patients provided written informed consent, and the patients did not receive chemotherapy or radiotherapy before the surgical procedure. Stool and urine samples were collected prior to the
surgery, from which genomic DNA was immediately extracted and then stored at -20°C. Cancer and pericarcinous tissue specimens were stored at -80°C for further use.

Following screening, a total of 87 CRC patients were recruited in the study, of which 56 cases were colon cancers and 31 cases were rectal cancers. In the study group, 52 were males and 35 were females, with an age range between 38 and 73 years, and a median age of 56. A cohort of 16 age-matched healthy subjects were recruited as a control, of which 9 were males and 6 were females, with an age range between 40 and 74 years, with a median age of 55.6.

**DNA isolation.** Homogenate-tissue DNA was extracted using the TGuide Tissue Genomic DNA Extraction kit [Tiangen Biotech (Beijing) Co., Ltd, Beijing, China]. DNA from fecal samples was extracted using a Stool DNA Extraction kit (Bioneer Corporation, Daedeok-gu, Republic of Korea). Genomic DNA was extracted from total blood, using a TGuide Blood Genomic DNA Extraction kit [Tiangen Biotech (Beijing) Co., Ltd,] according to the manufacturer’s instructions.

**Bisulfite modification of genomic DNA.** Following bisulfite modification, the unmethylated cytosine in genomic DNA will not be converted to uracil, whereas methylated cytosine will not be converted. Tissue genomic DNA methylation was performed using a Wizard DNA Clean-up system (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions. Stool and blood genomic DNA methylation were performed using an EZ DNA Methylation TM-Direct kit (Zymo Research Corporation, Irvine, CA, USA), according to the manufacturer’s instructions.

**n-MSP.** The n-MSP was performed to identify the expression of NDRG4 genes from blood, urine, stool and tissue. The primer sequences and polymerase chain reaction (PCR) conditions for the n-MSP approach have been previously described (18,19). The primer sequences, annealing temperatures, and PCR sizes are listed in Table I. Methylated DNA from normal human lymphocytes, which was treated by SssI methylase (New England BioLabs, Ipswich, MA, USA) was prepared as the positive control for methylated (M) amplifications, and DNA from untreated lymphocytes served as a negative control for unmethylated (U) amplifications.

The n-MSP of NDRG4 was performed in a 25-µl reaction volume, with 0.5 µl Taq polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA) and 2 µl DNA template. The NDRG4 gene cycling conditions for the first round were as follows: 95°C for 15 min; 25 cycles of 95°C for 30 sec, 56°C for 30 sec, and 72°C for 30 sec; final extension at 72°C for 7 min. The cycling conditions for the second round were as follows: Preheating at 95°C for 15 min, 35 cycles of 95°C for 30 sec, 66°C for 30 sec, and 72°C for 30 sec; final extension at 72°C for 7 min. MSP products were analyzed by 2% polyacrylamide gel electrophoresis, and a product size of 100 bp was expected for the NDRG4 gene.

**Statistical analysis.** A χ² test was used for methylation detection rate comparison between each sample of NDRG4. P<0.05 was considered to indicate a statistically significant difference. SPSS 13.0 software was used for all statistical analyses (SPSS, Inc., Chicago, IL, USA).

**Results**

**Rate of NDRG4 methylation.** nMSP detection was successfully used to assess for methylated NDRG4 in carcinoma and paracarcinoma tissues, feces, urine and blood of the 84 CRC

---

*Table I. Primer sequences, annealing temperatures, and product sizes used for nested methylation-specific polymerase chain reaction, to analyze the methylation status of the NDRG4 promoter.*

| Primer sequence | Temperature, °C | Product size, bp |
|-----------------|----------------|-----------------|
| Outer           |                |                 |
| NDRG4-F: 5'-GGTTYGTYYGGGATTAGTTTAGG-3' | 56 | 257 |
| NDRG4-R: 5'-CRAACAAACAAAACCCCCCT-3' |     |     |
| Inner           |                |                 |
| Methylated      |                |                 |
| NDRG4-UF: 5'-GATTAGTTTTAGGTATGTTTTG-3' | 66 | 100 |
| NDRG4-UR: 5'-AAAACCAAACCTATAACACCA-3' |     |     |
| Un-methylated   |                |                 |
| NDRG4-MF: 5'-TTTAGGTTGGTATCGTTTCGC-3' | 66 | 88 |
| NDRG4-MR: 5'-CGAACTAAAACGATACGCCG-3' |     |     |

bp, base pairs; F, forward; R, reverse; U, unmethylated; M, methylated.
cases (Fig. 1). The positive rate of methylated NDRG4 gene expression was 81% (68/84) in carcinoma tissues, while the positive rate was only 8.3% (7/84) in paracarcinoma tissues. There was a significant difference in the levels of methylated NDRG4 in carcinoma as compared with the paracarcinoma tissues (P<0.01). The sensitivity and specificity of NDRG4 gene detection in the diagnosis of CRC was 81 (68/84) and 91.7% (77/84) in tissues, respectively.

In addition to analysis in the tissues, the sensitivity and specificity of methylated NDRG4 in feces, urine and blood were 54.8 and 78.1% in blood; 72.6 and 85% in urine; 76.2 and 89.1% in feces. Methylated NDRG 4 genes in feces and urine showed a higher sensitivity and specificity for diagnosis than blood. From the present data, it could be suggested that a combination of using urine and fecal samples to detect the methylation status of NDRG4 could be a beneficial diagnostic method for CRC.

Highly expressed methylated NDRG 4 gene in tissue and feces DNA of CRC patients. The association between methylated NDRG4 and clinical pathological parameters were analyzed. The data showed no correlation between all methylated NDRG4 with age, the degree of tumor differentiation and TNM stage. Methylated NDRG4 in metastasis-lymph node tumors from CRC tissues and feces was significantly highly expressed as compared with non-metastatic samples (P<0.05). Methylated NDRG4 was not expressed highly in urine or blood samples (Table II).

Early diagnosis of colorectal cancer by methylated NDRG 4 gene in urine. According to the above research results, we recruited another 76 CRC patients; they all were confirmed by pathology diagnosis, the median age of them was 54 years (range, 39-71), and 36 non-cancer patients were selected as the normal control group. Urine specimens were collected preoperatively in all patients, with a collection volume of 50-100 ml, then sent to the laboratory immediately, where genomic DNA were extracted and then frozen at -20°C. All patients did not receive preoperative chemotherapy or radiotherapy, and informed consent was obtained. Of the 76 CRC patients, the proportion of positive methylated NDRG 4 gene status was 72.4% (55/76). This result showed consistency with the former experiments; combining the convenience and sensitivity, methylated NDRG 4 gene testing in urine could be a potential testing method.

**Discussion**

The formation of a solid tumor is a multi-staged process that results in abnormal gene expression. Epigenomic changes are an important cause of tumorigenesis, and methylated cytosine has been previously reported as an important factor in this process (20,21). During the process of proliferation, cellular nucleoside production is increased. Modified intracellular nucleosides are difficult to degrade, and can only be excreted through the urine. The level of urinary modified nucleosides can therefore be used as a reflection of the in vivo metabolic rate of nucleosides. During the process of canceration, the level of urinary modified nucleosides markedly increase, therefore, analysis of modified nucleosides in the urine could facilitate

### Table II. Association between methylated NDRG4 gene expression and clinicopathological parameters of colorectal cancer.

| Object            | Tissue | Blood | Urine | Stool |
|-------------------|--------|-------|-------|-------|
|                   | Total  | Methylated | Unmethylated | Total  | Methylated | Unmethylated | Methylated | Unmethylated | Methylated | Unmethylated |
| Age, years        | <65    | 36     | 29    | 7     | 26     | 17        |
|                   | ≥65    | 48     | 39    | 9     | 38     | 10        |
| Differentiation   | High-middle | 57       | 49    | 8     | 45     | 12        |
|                   | Low    | 27     | 19    | 8     | 19     | 8         |
| Lymph node metastasis | Exist | 55     | 50    | 5     | 48     | 7         |
|                   | None   | 29     | 18    | 11    | 16     | 10        |
| TNM stage         | I-II  | 48     | 42    | 6     | 39     | 9         |
|                   | III-IV | 36    | 26    | 10    | 13     | 2         |

*P<0.05, TNM Classification of Malignant Tumors cancer staging system (36)*.
preliminary tumor detection. DNA methylation is one of the predominant mechanisms leading to loss of gene function (22). Data has shown that CRC is a tumor type that is prone to high levels of abnormal gene methylation (23,24). Previous studies have indicated that methylation of multiple genes can accurately reflect CRC much more than single gene methylation (25,26).

Previous reports have shown that DNA fragments from tumor genes have been successfully isolated from the urine of patients who have been diagnosed with CRC (27,28). These studies have therefore demonstrated that DNA testing from urine samples may be a feasible method for the diagnosis of early-stage cancer. As compared with plasma or sera diagnoses, a urinalysis can eliminate the possibility of blood infection (29). In addition, the amount of tumor DNA that can be obtained from peripheral blood serum is low (ng), as compared with tissue samples, and the majority of DNA can be readily degraded during the process of modification by NaHSO₄. For trace DNA samples, the sensitivity of the conventional n-MSP method requires improvements (18).

Ahquist et al (30) found that DNA isolated from feces has improved sensitivity in methylated gene detection as compared with DNA extracted from peripheral blood (30,31), particularly in early-stage CRC. This may be associated with the direct contact with the colorectal tissue and the alkaline environment in which colorectal cells are exposed to. Conversely, low DNA levels in the peripheral blood and the presence of numerous factors in the plasma could influence the PCR reaction (32,33). In the present study, the methylated NDRG4 gene expression rates in the tumor and adjacent tissues, were 81 and 8.3%. This rate of methylation at the CpG site, however, was not significantly associated with age, differentiation level or TNM stage.

The NDRG4 transcript is 32 Kb long, consisting of 17 exons and 16 introns. The function of NDRG4 in tumor development remains unclear, but numerous studies have indicated that NDRG4 is associated with the growth, differentiation and metastasis of the tumor (17,34,35). The 5’ regulatory region of NDRG4 contains the CpG island, and is often methylated in the occurrence and development of CRC, thus the methylation of NDRG4 is considered to be an important biological feature of colorectal cancer (17). Melotte et al (16) identified that NDRG4 is a biomarker candidate tumor suppressor gene in CRC, and methylation of the NDRG4 promoter can be used as a biological marker for the detection of colorectal cancer. The sensitivity and specificity of NDRG4 methylation were 61 and 93% in the fecal samples analyzed.

In the present study, n-MSP was used to detect methylated NDRG4. The sensitivity and specificity was 76.2 and 89.15% in stool samples and 72.6 and 85% in urine samples. This indicated that, as compared with blood samples, methylated NDRG4 in DNA isolated from feces and urine, can be used as a non-invasive biomarker for the detection of early stage CRC. This method could be used to enrich the current diagnostic methods of CRC. Urine contains significantly less protein than that of blood, therefore the isolation of DNA fragments from urine is facilitated. Urine samples are easy to obtain, and have high stability, reproducibility and specificity. The methylation of NDRG4 may therefore become a standard measure in the clinical diagnosis of CRC.

In conclusion, the present study has demonstrated that the detection of NDRG4 methylation status in feces and urine has sufficient sensitivity and specificity as a diagnostic measure in CRC. Considering the advantages of easy acquisition of urine samples, detection of NDRG4 methylation in urine could be suitable for detecting low levels of methylated genes, to facilitate the early diagnosis of CRC.

Acknowledgements

The authors would like to thank the Research Fund of the PLA General Hospital (Beijing, China) for financial support.

References

1. Todosi AM, Gavrilnescu MM, Anijei GM, et al: Colon cancer at the molecular level - usefulness of epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med Nat Iasi 116: 1106-1111, 2012.
2. Wallace PM and Suzuki R: Regional, racial, and gender differences in colorectal cancer screening in middle-aged African-Americans and Whites. J Cancer Educ 27: 703-708, 2012.
3. Zauber AG, Winawer SJ, O’Brien MJ, et al: Colonoscopy polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366: 687-696, 2012.
4. Nagasaka T, Mori Y, Umeda Y and Fujiwara T: Biomarker for colorectal cancer. Nihon Rinsho 70: 802-808, 2012 (In Japanese).
5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714, 2004.
6. Sonnenberg A and Delcò F: Cost-effectiveness of a single colono-scopy in screening for colorectal cancer. Arch Intern Med 162: 163-168, 2002.
7. Lind OE, Danielsen SA, Ahquist T, et al: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 10: 85, 2011.
8. Mori Y, Olaru AV, Cheng Y, et al: Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 18: 465-478, 2011.
9. Jin X, Lin M, Zhang H, et al: Serum biomarkers of colorectal cancer with AU and NP20 chips including a diagnosis model. Hepatogastroenterology 59: 124-129, 2012.
10. Lenhard K, Bommer GT, Asutay S, et al: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 3: 142-149, 2005.
11. Lange CP, Campan M, Hinoue T, et al: Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PloS One 7: e50266, 2012.
12. Cassinotti E, Nelson J, Liggett T, et al: DNA methylation patterns in blood of patients with colorectal cancer and adenomatous polyps. Int J Cancer 131: 1153-1157, 2012.
13. Lange CP and Laird PW: Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics 5: 105-108, 2013.
14. Ahquist DA, Zou H, Domanico M, et al: Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142: 248-256, 2012.
15. Yamamoto H, Kokame K, Ôkuda T, et al: NDRG4 protein-deficient mice exhibit spatial learning deficits and vulnerabilities to cerebral ischemia. J Biol Chem 286: 26158-26165, 2011.
16. Melotte V, Lentjes MH, van den Bosch SM, et al: N-Myocardin downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101: 916-927, 2009.
17. Kotipatruni RP, Ferraro DJ, Ren X, et al: NDRG4, the N-Myocardin downstream regulated gene, is important for cell survival, tumor invasion and angiogenesis in meningiomas. Integr Biol (Camb) 4: 1185-1197, 2012.
18. Fan LP, Shen JZ, Ye BG, et al: Detection of p16 gene methylation status in adult patients with acute leukemia by using n-MSP. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15: 258-261, 2007.
19. Carraway HE, Wang S, Blackford A, et al: Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Res Treat 114: 315-325, 2009.
20. Ryan HE, Lo J and Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998.
21. Yi JM, Dhir M, Guzzetta AA, et al: DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol 33: 363-372, 2012.
22. Ziyab AH, Karmaus W, Holloway JW, et al: DNA methylation of the filaggrin gene adds to the risk of eczema associated with loss-of-function variants. J Eur Acad Dermatol Venereol 27: e420-e423, 2013.

23. Morioka Y, Hibi K, Sakai M, et al: Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res 26: 1791-1795, 2006.

24. de la Chapelle A and Hampel H: Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28: 3380-3387, 2010.

25. Uehara E, Takeuchi S, Yang Y, et al: Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett 3: 190-192, 2012.

26. Zhao YF, Zhang YG, Tian XX, Juan D and Jie Z: Aberrant methylation of multiple genes in gastric carcinomas. Int J Surg Pathol 15: 242-251, 2007.

27. Samejima K, Hiramatsu K, Takahashi K, et al: Identification and determination of urinary acetylpolyamines in cancer patients by electrospray ionization and time-of-flight mass spectrometry. Anal Biochem 401: 22-29, 2010.

28. Cai H, Thomasset SC, P-Berry D, et al: Determination of anthocyanins in the urine of patients with colorectal liver metastases after administration of bilberry extract. Biomed Chromatogr 25: 660-663, 2011.

29. Jackson C, Best N and Elliott P: UK Biobank Pilot Study: stability of haematological and clinical chemistry analytes. Int J Epidemiol 37 Suppl 1: i16-i22, 2008.

30. Ahlquist DA, Taylor WR, Mahoney DW, et al: The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 10: 272-277, 2012.

31. deVos T, Tetzner R, Model F, et al: Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55: 1337-1346, 2009.

32. Lacks S and Greenberg B: Complementary specificity of restriction endonucleases of Diplococcus pneumoniae with respect to DNA methylation. J Mol Biol 114: 153-168, 1977.

33. Hastings ML, Palma J and Duelli DM: Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods 58: 144-150, 2012.

34. Ding W, Zhang J, Yoon JG, Shi D, Foltz G and Lin B: NDRG4 is downregulated in glioblastoma and inhibits cell proliferation. OMICS 16: 263-267, 2012.

35. Yang X, An L and Li X: NDRG3 and NDRG4, two novel tumor-related genes. Biomed Pharmacother 67: 681-684, 2013.

36. Hayashi T, Yoshikawa T, Bonam K, et al: The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer 119: 1330-1337, 2013.